HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status

Overexpression of HER2 is an important prognostic marker, and the only predictive biomarker of response to HER2-targeted therapies in invasive breast cancer. HER2-HER3 dimer has been shown to drive proliferation and tumor progression, and targeting of this dimer with pertuzumab alongside chemotherapy and trastuzumab, has shown significant clinical utility. The purpose of this study was to accurately quantify HER2-HER3 dimerisation in formalin fixed paraffin embedded (FFPE) breast cancer tissue as a novel prognostic biomarker. FFPE tissues were obtained from patients included in the METABRIC (Molecular Taxonomy of Breast Cancer International Consortium) study. HER2-HER3 dimerisation was quantified using an improved fluorescence lifetime imaging microscopy (FLIM) histology-based analysis. Analysis of 131 tissue microarray cores demonstrated that the extent of HER2-HER3 dimer formation as measured by Förster Resonance Energy Transfer (FRET) determined through FLIM predicts the likelihood of metastatic relapse up to 10 years after surgery (hazard ratio 3.91 (1.61–9.5), p = 0.003) independently of HER2 expression, in a multivariate model. Interestingly there was no correlation between the level of HER2 protein expressed and HER2-HER3 heterodimer formation. We used a mathematical model that takes into account the complex interactions in a network of all four HER proteins to explain this counterintuitive finding. Future utility of this technique may highlight a group of patients who do not overexpress HER2 protein but are nevertheless dependent on the HER2-HER3 heterodimer as driver of proliferation. This assay could, if validated in a group of patients treated with, for instance pertuzumab, be used as a predictive biomarker to predict for response to such targeted therapies.

[1]  Melanie Keppler,et al.  The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress , 2009, Nature.

[2]  D Barnes,et al.  Imaging protein kinase Calpha activation in cells. , 1999, Science.

[3]  T. Ng,et al.  Imaging proteins in vivo using fluorescence lifetime microscopy. , 2007, Molecular bioSystems.

[4]  Jong-Hyeon Jeong,et al.  Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. , 2013, Journal of the National Cancer Institute.

[5]  M. Parsons,et al.  Intracellular coupling of adhesion receptors: molecular proximity measurements. , 2002, Methods in cell biology.

[6]  S. Ameer-Beg,et al.  The Gray Institute ‘open’ high-content, fluorescence lifetime microscopes , 2013, Journal of microscopy.

[7]  M. Piccart,et al.  Resistance to trastuzumab: a necessary evil or a temporary challenge? , 2002, Clinical breast cancer.

[8]  Sung-Bae Kim,et al.  Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. , 2013, The Lancet. Oncology.

[9]  Luis P. Fernandes,et al.  A Targeted siRNA Screen Identifies Regulators of Cdc42 Activity at the Natural Killer Cell Immunological Synapse , 2011, Science Signaling.

[10]  M. Gnant,et al.  Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  John Kuriyan,et al.  Structural analysis of the catalytically inactive kinase domain of the human EGF receptor 3 , 2009, Proceedings of the National Academy of Sciences.

[12]  A. Chaudhuri,et al.  HER2 Status and Benefit from Adjuvant Trastuzumab in Breast Cancer , 2008 .

[13]  A. Coolen,et al.  The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients , 2009, Targeted Oncology.

[14]  Alastair I. Bartlett,et al.  Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition. , 2011, American journal of clinical pathology.

[15]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[16]  H. Wiley,et al.  ErbB-2 Amplification Inhibits Down-regulation and Induces Constitutive Activation of Both ErbB-2 and Epidermal Growth Factor Receptors* , 1999, The Journal of Biological Chemistry.

[17]  S. Ameer-Beg,et al.  Multiphoton time-domain fluorescence lifetime imaging microscopy: practical application to protein–protein interactions using global analysis , 2009, Journal of the Royal Society Interface.

[18]  W. Gullick,et al.  Intracellular expression of the truncated extracellular domain of c-erbB-3/HER3. , 2001, Cellular signalling.

[19]  S. Chandarlapaty,et al.  HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies , 2011, Expert review of anticancer therapy.

[20]  B. Kholodenko,et al.  Ligand-dependent responses of the ErbB signaling network: experimental and modeling analyses , 2007, Molecular systems biology.

[21]  M. Piccart,et al.  Beyond trastuzumab and lapatinib: new options for HER2-positive breast cancer . , 2013, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[22]  William Pao,et al.  Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase , 2011, Proceedings of the National Academy of Sciences.

[23]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[24]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[25]  Sung-Bae Kim,et al.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. , 2012, The New England journal of medicine.

[26]  V. Goh,et al.  The challenges of integrating molecular imaging into the optimization of cancer therapy. , 2011, Integrative biology : quantitative biosciences from nano to macro.

[27]  D. Amadori,et al.  Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA) , 2013, Breast Cancer Research and Treatment.

[28]  Tony Ng,et al.  Quantification of HER family receptors in breast cancer , 2015, Breast Cancer Research.

[29]  S. Achilefu,et al.  Fluorescence lifetime measurements and biological imaging. , 2010, Chemical reviews.

[30]  B. Vojnovic,et al.  Multiphoton-FLIM quantification of the EGFP-mRFP1 FRET pair for localization of membrane receptor-kinase interactions. , 2005, Biophysical journal.

[31]  R. Landgraf,et al.  Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling , 2012, Proceedings of the National Academy of Sciences.

[32]  F. Maurer,et al.  The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[33]  P. R. Barber,et al.  The Gray Institute open microscopes applied to radiobiology and protein interaction studies , 2014, Photonics West - Biomedical Optics.

[34]  Haluk Resat,et al.  Bmc Cell Biology Her/erbb Receptor Interactions and Signaling Patterns in Human Mammary Epithelial Cells , 2009 .

[35]  M. Dowsett,et al.  Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039) , 2014, Clinical Cancer Research.

[36]  J. Bartlett,et al.  In situ detection of HER2:HER2 and HER2:HER3 protein–protein interactions demonstrates prognostic significance in early breast cancer , 2012, Breast Cancer Research and Treatment.

[37]  Ryuji Kobayashi,et al.  Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. , 2005, Cancer research.

[38]  J. Siegel,et al.  Fluorescence lifetime imaging of unstained tissues: early results in human breast cancer , 2003, The Journal of pathology.

[39]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[40]  A. Coolen,et al.  Imaging tumour heterogeneity of the consequences of a PKCα-substrate interaction in breast cancer patients. , 2014, Biochemical Society transactions.

[41]  Borivoj Vojnovic,et al.  Global and pixel kinetic data analysis for FRET detection by multi-photon time-domain FLIM , 2005, SPIE BiOS.

[42]  U. Landegren,et al.  Direct observation of individual endogenous protein complexes in situ by proximity ligation , 2006, Nature Methods.

[43]  Borivoj Vojnovic,et al.  Bayesian analysis of fluorescence lifetime imaging data , 2011, BiOS.

[44]  Erez M. Bublil,et al.  Kinase‐mediated quasi‐dimers of EGFR , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[45]  S. Tsai,et al.  EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy , 2008, Oncogene.

[46]  J. Lambert,et al.  Lifetime and diffusion of singlet oxygen in a cell. , 2005, The journal of physical chemistry. B.

[47]  John M S Bartlett,et al.  Updated UK Recommendations for HER2 assessment in breast cancer , 2014, Journal of Clinical Pathology.

[48]  Douglas Lauffenburger,et al.  HER2-mediated effects on EGFR endosomal sorting: analysis of biophysical mechanisms. , 2003, Biophysical journal.

[49]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2014, Archives of pathology & laboratory medicine.

[50]  P. Grambsch,et al.  A Package for Survival Analysis in S , 1994 .

[51]  E. Perez,et al.  EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trial , 2014, British Journal of Cancer.

[52]  I. Ellis,et al.  Best Practice No 176 , 2004, Journal of Clinical Pathology.

[53]  J. Baselga,et al.  Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  Carlos L Arteaga,et al.  HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. , 2006, Cancer cell.

[55]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[56]  A. Citri,et al.  The deaf and the dumb: the biology of ErbB-2 and ErbB-3. , 2003, Experimental cell research.

[57]  Stephen Williams,et al.  Profiling the HER3/PI3K Pathway in Breast Tumors Using Proximity-Directed Assays Identifies Correlations between Protein Complexes and Phosphoproteins , 2011, PloS one.

[58]  Yoshikazu Ohta,et al.  Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein , 2011, The Journal of Biological Chemistry.

[59]  B. Vojnovic,et al.  Effect of Phosphorylation on EGFR Dimer Stability Probed by Single-Molecule Dynamics and FRET/FLIM , 2015, Biophysical journal.